Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Watson Profit Jumps; Company Raises Its Outlook

By Pharmaceutical Processing | May 10, 2010

MORRISTOWN, N.J. (AP) — Watson Pharmaceuticals Inc. said today its first-quarter net income jumped 42 percent with generic sales getting a boost from a recent acquisition overseas. The company raised its outlook for the year.

Global generics revenue climbed 35 percent in the quarter to $543.8 million, partially due to the addition of product sales from new international markets.

Watson completed its $1.75 billion buyout of Arrow Group, based in London, in December.

Arrow owns the U.S. rights to the authorized generic version of Pfizer Inc.’s cholesterol drug Lipitor, which is one of the best-selling brand-name drug in the world.

Watson said first-quarter net income was $69.8 million, or 57 cents per share, in the three months that ended March 31. That compares with $49.1 million, or 43 cents per share, in the first quarter of 2009.

Adjusted for acquisitions and other one-time costs, per-share earnings were 81 cents, compared with 69 cents last year.

Revenue rose 28 percent to $856.5 million, and the company’s adjusted net income was 81 cents per share.

Analysts polled by Thomson Reuters expected, on average, earnings of 74 cents per share on $829.49 million in revenue.

The company said it now expects 2010 adjusted earnings to be between $3.25 and $3.45 per share. Watson said in February it expected $3.05 and $3.30 per share.

Analysts, on average, forecast $3.26 per share.

The company said revenue from its global brands segment fell 18 percent to $91.3 million in the quarter. Cost of sales, excluding amortization, rose 30 percent to $504.7 million, and total operating expenses were up 29 percent to $756.2 million.

 

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE